CLINICAL RESEARCH
Association of anthropometrically predicted visceral adipose tissue with mortality in patients with non-alcoholic fatty liver disease: a cohort study
More details
Hide details
1
Department of Endocrinology, Affiliated Kunshan Hospital of Jiangsu University, Kunshan, Jiangsu, China
These authors had equal contribution to this work
Submission date: 2025-10-04
Final revision date: 2025-10-17
Acceptance date: 2025-10-28
Online publication date: 2026-01-12
Corresponding author
Zhaoxiang Wang
Department of Endocrinology
Affiliated Kunshan Hospital
of Jiangsu University
Kunshan, Jiangsu
215300, China
Shao Zhong
Department of Endocrinology
Affiliated Kunshan Hospital
of Jiangsu University
Kunshan, Jiangsu
215300, China
KEYWORDS
TOPICS
ABSTRACT
Introduction:
The objective of this study was to evaluate the association between anthropometrically predicted visceral adipose tissue (apVAT) and mortality among individuals with non-alcoholic fatty liver disease (NAFLD).
Material and methods:
This study analyzed 6206 NAFLD participants from the National Health and Nutrition Examination Survey. NAFLD was identified using the United States Fatty Liver Index (USFLI) or Fatty Liver Index (FLI). Baseline apVAT, an estimate of visceral fat derived from anthropometric parameters including age, body mass index (BMI), waist circumference (WC), and thigh circumference, was calculated using validated sex-specific equations. Mortality outcomes were determined by linking data to National Death Index (NDI) records up to December 31, 2019. Cox proportional hazards models and restricted cubic splines were used to examine associations, and time-dependent receiver operating characteristic (ROC) analyses were used to compare apVAT with other obesity indices including BMI, WC, thigh circumference, waist-to-height ratio (WHtR), relative fat mass (RFM), and weight-adjusted waist index (WWI).
Results:
During a median follow-up period of 187 months, 1884 deaths from all causes and 517 from cardiovascular causes were observed. Multivariable-adjusted Cox analysis showed that the highest apVAT quartile had hazard ratios of 3.83 (3.01–4.87) for all-cause mortality and 3.47 (2.13–5.65) for cardiovascular mortality, compared to the lowest quartile. A nonlinear relationship between apVAT and mortality risk was identified. apVAT showed the highest predictive value for mortality risk compared with BMI, WC, thigh circumference, WHtR, RFM, and WWI.
Conclusions:
Elevated apVAT levels are correlated with increased mortality risk in NAFLD, highlighting its potential as a prognostic marker.
REFERENCES (46)
1.
Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease. Lancet 2021; 397: 2212-24.
2.
Quek J, Chan KE, Wong ZY, et al. Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2023; 8: 20-30.
3.
Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology 2023; 77: 1335-47.
4.
Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol 2015; 62 (1 Suppl): S47-64.
5.
Kasper P, Martin A, Lang S, et al. NAFLD and cardiovascular diseases: a clinical review. Clin Res Cardiol 2021; 110: 921-37.
6.
Polyzos SA, Kountouras J, Mantzoros CS. Obesity and nonalcoholic fatty liver disease: from pathophysiology to therapeutics. Metabolism 2019; 92: 82-97.
7.
Machado MV, Cortez-Pinto H. NAFLD, MAFLD and obesity: brothers in arms? Nat Rev Gastroenterol Hepatol 2023; 20: 67-8.
8.
Zhang X, Ha S, Lau HC, Yu J. Excess body weight: novel insights into its roles in obesity comorbidities. Semin Cancer Biol 2023; 92: 16-27.
9.
Yang L, Ge Y, Zhu Q, et al. The combination of fat distribution and BMI redefines obesity: Result From NHANES. J Cachexia Sarcopenia Muscle 2025; 16: e70013.
10.
Tao M, Zhou G, Liu J, et al. Visceral adipose tissue and risk of nonalcoholic fatty liver disease: a Mendelian randomization study. Clin Endocrinol 2023; 99: 370-7.
11.
Saponaro C, Sabatini S, Gaggini M, et al. Adipose tissue dysfunction and visceral fat are associated with hepatic insulin resistance and severity of NASH even in lean individuals. Liver Int 2022; 42: 2418-27.
12.
Bansal S, Vachher M, Arora T, Kumar B, Burman A. Visceral fat: a key mediator of NAFLD development and progression. Human Nutr Metabol 2023; 33: 200210.
13.
Hardy OT, Czech MP, Corvera S. What causes the insulin resistance underlying obesity? Curr Opin Endocrinol Diabetes Obes 2012; 19: 81-7.
14.
Godoy-Matos AF, Silva Júnior WS, Valerio CM. NAFLD as a continuum: from obesity to metabolic syndrome and diabetes. Diabetol Metab Syndr 2020; 12: 60.
15.
Fang H, Berg E, Cheng X, Shen W. How to best assess abdominal obesity. Curr Opin Clin Nutr Metab Care 2018; 21: 360-5.
16.
Wu X, Song Y, Wu S. The development and evaluation of nine obesity-based indices for gallstones in U.S. adults. Int J Surg 2025; 111: 2348-57.
17.
Forero Torres AY, Forero LC. Comparison between anthropometric measurements and indices to evaluate general and abdominal obesity, Colombia ENSIN 2015. Biomedica 2023; 43: 88-98.
18.
Brown JC, Harhay MO, Harhay MN. Anthropometrically predicted visceral adipose tissue and blood-based biomarkers: a cross-sectional analysis. Eur J Nutr 2018; 57: 191-8.
19.
Millar SR, Perry IJ, Phillips CM. Anthropometric measures, predicted visceral adipose tissue and biomarkers of chronic inflammation. Eur J Clin Invest 2024; 54: e14104.
20.
Samouda H, Dutour A, Chaumoitre K, Panuel M, Dutour O, Dadoun F. VAT=TAAT-SAAT: innovative anthropometric model to predict visceral adipose tissue without resort to CT-Scan or DXA. Obesity 2013; 21: E41-50.
21.
Brown JC, Harhay MO, Harhay MN. Anthropometrically-predicted visceral adipose tissue and mortality among men and women in the third national health and nutrition examination survey (NHANES III). Am J Hum Biol 2017; 29: 10.1002/ajhb.22898.
22.
Zhao H, Wu J, Wu Q, Shu P. Systemic immune-inflammation index values are associated with non-melanoma skin cancers: evidence from the National Health and Nutrition Examination Survey 2010-2018. Arch Med Sci 2024; 20: 1128-37.
23.
Zhao J, Zhang T, Zhu Y, et al. High-density lipoprotein cholesterol and nuclear factor I A in type 2 diabetes and mild cognitive impairment: biomarkers and mechanistic insights. Arch Med Sci 2025;
https://doi.org/10.5114/aoms/2....
24.
Li M, Yu X, Zhang W, et al. The association between weight-adjusted-waist index and depression: results from NHANES 2005-2018. J Affect Disord 2024; 347: 299-305.
25.
Qiu J, Li J, Xu S, et al. Triglyceride glucose-weight-adjusted waist index as a cardiovascular mortality predictor: incremental value beyond the establishment of TyG-related indices. Cardiovasc Diabetol 2025; 24: 306.
26.
Woolcott OO, Bergman RN. Relative fat mass (RFM) as a new estimator of whole-body fat percentage – a cross-sectional study in American adult individuals. Sci Rep 2018; 8: 10980.
27.
Ruhl CE, Everhart JE. Fatty liver indices in the multiethnic United States National Health and Nutrition Examination Survey. Aliment Pharmacol Ther 2015; 41: 65-76.
28.
Kaneva AM, Bojko ER. Fatty liver index (FLI): more than a marker of hepatic steatosis. J Physiol Biochem 2024; 80: 11-26.
29.
Moshfegh AJ, Rhodes DG, Baer DJ, et al. The US Department of Agriculture Automated Multiple-Pass Method reduces bias in the collection of energy intakes. Am J Clin Nutr 2008; 88: 324-32.
30.
Simati S, Kokkinos A, Dalamaga M, Argyrakopoulou G. Obesity paradox: fact or fiction? Curr Obes Rep 2023; 12: 75-85.
31.
Donini LM, Pinto A, Giusti AM, Lenzi A, Poggiogalle E. Obesity or BMI paradox? Beneath the tip of the iceberg. Front Nutr 2020; 7: 53.
32.
Rubino F, Puhl RM, Cummings DE, et al. Joint international consensus statement for ending stigma of obesity. Nat Med 2020; 26: 485-97.
33.
Antonopoulos AS, Oikonomou EK, Antoniades C, Tousoulis D. From the BMI paradox to the obesity paradox: the obesity-mortality association in coronary heart disease. Obes Rev 2016; 17: 989-1000.
34.
Neeland IJ, Poirier P, Després JP. Cardiovascular and metabolic heterogeneity of obesity: clinical challenges and implications for management. Circulation 2018; 137: 1391-406.
35.
Zong G, Zhang Z, Yang Q, Wu H, Hu FB, Sun Q. Total and regional adiposity measured by dual-energy X-ray absorptiometry and mortality in NHANES 1999-2006. Obesity 2016; 24: 2414-21.
36.
Lee DH, Keum N, Hu FB, et al. Predicted lean body mass, fat mass, and all cause and cause specific mortality in men: prospective US cohort study. BMJ 2018; 362: k2575.
37.
Sedlmeier AM, Baumeister SE, Weber A, et al. Relation of body fat mass and fat-free mass to total mortality: results from 7 prospective cohort studies. Am J Clin Nutr 2021; 113: 639-46.
38.
Zhang Y, Xu J, Zhang Y, Chen Y, Liu Q. J-shaped association between metabolic score for visceral fat and albuminuria risk: a population-based study. Front Endocrinol 2025; 16: 1649521.
39.
Katzer K, Hill JL, McIver KB, Foster MT. Lipedema and the potential role of estrogen in excessive adipose tissue accumulation. Int J Mol Sci 2021; 22: 11720.
40.
Després JP. Body fat distribution and risk of cardiovascular disease: an update. Circulation 2012; 126: 1301-13.
41.
Neeland IJ, Ross R, Després JP, et al. Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement. Lancet Diabetes Endocrinol 2019; 7: 715-25.
42.
Chen X, Liu X. Weekend warrior physical activity patterns can reduce the risk of gallstone formation: NHANES 2017-2020 and Mendelian randomization analyses. Arch Med Sci
https://doi.org/10.5114/aoms/2....
43.
Yao J, Chen X, Xin Y, et al. Association between Healthy Eating Index 2015 and metabolic syndrome among US cancer survivors: evidence from NHANES 2005-2016. Int J Food Sci Nutr 2025; 76: 315-25.
44.
Cena H, Calder PC. Defining a healthy diet: evidence for the role of contemporary dietary patterns in health and disease. Nutrients 2020; 12: 334.
45.
Targher G, Byrne CD, Tilg H. MASLD: a systemic metabolic disorder with cardiovascular and malignant complications. Gut 2024; 73: 691-702.
46.
Younossi ZM, Paik JM, Stepanova M, Ong J, Alqahtani S, Henry L. Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease. J Hepatol 2024; 80: 694-701.